Market revenue in 2023 | USD 2,380.0 million |
Market revenue in 2030 | USD 4,102.1 million |
Growth rate | 8.1% (CAGR from 2023 to 2030) |
Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
Fastest growing segment | Antibody Drug Conjugate (ADC |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC |
Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.
Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 40.02% in 2023. Horizon Databook has segmented the Australia active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.
Australia accounted for 6.7% of Asia Pacific’s market in 2020. In Australia, there are nearly 400 domestic biotechnology firms and 50 multinational companies operating as subsidiaries, including Pfizer, GSK, Bristol-Myers Squibb, Merck, and Novartis.
Presence of a large number of local and foreign companies is anticipated to boost manufacturing activities, thereby fueling the market. Furthermore, aligning with GMPs across various jurisdictions by the Australian Therapeutic Goods Administration (TGA), the U.S. FDA, and the EMA is anticipated to facilitate market entry of U.S. and European firms in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Australia active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account